Comparative Pharmacology
Head-to-head clinical analysis: RIFADIN versus RIFAMPICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIFADIN versus RIFAMPICIN.
RIFADIN vs Rifampicin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA-dependent RNA polymerase in bacterial cells, blocking RNA transcription.
Inhibits bacterial DNA-dependent RNA polymerase by binding to the beta subunit, thereby blocking RNA transcription.
600 mg orally or intravenously once daily, or 10 mg/kg/day (max 600 mg) for tuberculosis; for meningococcal prophylaxis, 600 mg orally twice daily for 2 days.
600 mg orally or intravenously once daily
None Documented
None Documented
Terminal elimination half-life: 3-5 hours initially, increases to 2-5 hours after repeated dosing due to autoinduction of metabolizing enzymes; in hepatic impairment: up to 5-10 hours.
Clinical Note
moderateRifampicin + Digoxin
"The metabolism of Digoxin can be increased when combined with Rifampicin."
Clinical Note
moderateRifampicin + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Rifampicin."
Clinical Note
moderateRifampicin + Torasemide
"The metabolism of Torasemide can be increased when combined with Rifampicin."
Clinical Note
moderateRifampicin + Deferasirox
"The serum concentration of Deferasirox can be decreased when it is combined with Rifampicin."
Terminal elimination half-life is 3-5 hours initially, but decreases to 2-3 hours after repeated dosing due to auto-induction of hepatic enzymes. Clinically significant for daily dosing and need for consistent timing.
Renal: ~30% unchanged; fecal/biliary: ~60-65% as metabolites (deacetylated form) and unchanged drug; enterohepatic circulation occurs.
Primarily hepatic (biliary) excretion into feces; about 60-65% as unchanged drug and metabolites. Renal elimination accounts for approximately 30% (mostly as metabolites). <5% excreted unchanged in urine.
Category C
Category C
Rifamycin Antibiotic
Rifamycin Antibiotic